{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T20:24:40Z","timestamp":1769977480897,"version":"3.49.0"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The assay of saliva samples provides a valuable alternative to the use of blood samples for therapeutic drug monitoring (TDM), at least for certain categories of patients. To determine the feasibility of using saliva sampling for the TDM of rufinamide, we compared rufinamide concentrations in paired samples of saliva and plasma collected from 26 patients with epilepsy at steady state. Within\u2010patient relationships between plasma rufinamide concentrations and dose, and the influence of comedication were also investigated. Assay results in the two tested fluids showed a good correlation (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a0.78, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.0001), but concentrations in saliva were moderately lower than those in plasma (mean saliva to plasma ratio = 0.7\u00a0\u00b1\u00a00.2). In eight patients evaluated at three different dose levels, plasma rufinamide concentrations increased linearly with increasing dose. Patients receiving valproic acid comedication had higher dose\u2010normalized plasma rufinamide levels than patients comedicated with drugs devoid of strong enzyme\u2010inducing or enzyme\u2010inhibiting activity. Overall, these findings indicate that use of saliva represents a feasible option for the application of TDM in patients treated with rufinamide. Because rufinamide concentrations are lower in saliva than in plasma, a correction factor is needed if measurements made in saliva are used as a surrogate for plasma concentrations.<\/jats:p>","DOI":"10.1111\/epi.16584","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T10:49:30Z","timestamp":1592650170000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy"],"prefix":"10.1111","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-4437","authenticated-orcid":false,"given":"Valentina","family":"Franco","sequence":"first","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology Department of Internal Medicine and Therapeutics University of Pavia Pavia Italy"},{"name":"IRCCS  Mondino Foundation Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Gatti","sequence":"additional","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology Department of Internal Medicine and Therapeutics University of Pavia Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iolanda","family":"Mazzucchelli","sequence":"additional","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology Department of Internal Medicine and Therapeutics University of Pavia Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Marchiselli","sequence":"additional","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology Department of Internal Medicine and Therapeutics University of Pavia Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Fattore","sequence":"additional","affiliation":[{"name":"IRCCS  Mondino Foundation Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rota","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Surgical, and Dental Sciences University of Milan Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Andrea","family":"Galimberti","sequence":"additional","affiliation":[{"name":"IRCCS  Mondino Foundation Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Capovilla","sequence":"additional","affiliation":[{"name":"Epilepsy Center C. Poma Hospital Mantua Italy"},{"name":"Fondazione Poliambulanza Brescia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Beccaria","sequence":"additional","affiliation":[{"name":"Epilepsy Center C. Poma Hospital Mantua Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"De Giorgis","sequence":"additional","affiliation":[{"name":"IRCCS  Mondino Foundation Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-8912","authenticated-orcid":false,"given":"Cecilie","family":"Johannessen Landmark","sequence":"additional","affiliation":[{"name":"Program for Pharmacy Faculty of Health Sciences Oslo Metropolitan University Oslo Norway"},{"name":"Section for Clinical Pharmacology Department of Pharmacology National Center for Epilepsy Oslo University Hospital Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-223X","authenticated-orcid":false,"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[{"name":"Division of Clinical and Experimental Pharmacology Department of Internal Medicine and Therapeutics University of Pavia Pavia Italy"},{"name":"IRCCS  Mondino Foundation Pavia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Banzel (rufinamide). Full prescribing information.Woodcliff Lake NJ:Eisai.Last revised February 2015. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021911s012lbl.pdf. Accessed April 16 2020."},{"key":"e_1_2_8_3_1","unstructured":"Inovelon (rufinamide). Summary of product characteristics.Hatfield UK:Eisai. Last revised July 2019. Available at:https:\/\/www.medicines.org.uk\/emc\/product\/410\/smpc.Accessed April 16 2020."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01665.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31827c11e7"},{"key":"e_1_2_8_7_1","first-page":"1","article-title":"Usefulness of saliva for perampanel therapeutic drug monitoring","author":"Kim DY","year":"2020","journal-title":"Epilepsia"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14023"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-5126-9"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13802"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936060-00006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31820fa9ad"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-015-0291-4"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2015.12.015"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/187231211798472511"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.16584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16584","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.16584","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.16584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:50:22Z","timestamp":1693907422000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.16584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,20]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/epi.16584"],"URL":"https:\/\/doi.org\/10.1111\/epi.16584","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,20]]},"assertion":[{"value":"2020-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}